3. Clinicopathological characteristics of patients with bilateral breast cancer.
| Clinicopathological
characteristics |
n (%) | P | |
| Left | Right | ||
| DCIS, ductal carcinoma in situ; LCIS, lobular carcinoma in situ; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; NA, not applicable; HR, hormone receptor; HER2, human epidermal growth factor receptor 2; TNBC, triple-negative breast cancer. | |||
| Histological type | 0.0524 | ||
| DCIS | 70 (15.9) | 90 (20.5) | |
| LCIS | 0 (0) | 4 (0.9) | |
| IDC | 287 (65.2) | 276 (62.7) | |
| ILC | 11 (2.5) | 6 (1.4) | |
| Other | 30 (6.8) | 35 (8.0) | |
| NA | 42 (9.5) | 29 (6.6) | |
| Malignancy grade | 0.7355 | ||
| I | 28 (6.4) | 31 (7.0) | |
| II | 178 (40.5) | 167 (38.0) | |
| III | 77 (17.5) | 73 (16.6) | |
| Carcinoma in situ | 41 (9.3) | 53 (12.0) | |
| Other | 55 (12.5) | 49 (11.1) | |
| NA | 61 (13.9) | 67 (15.2) | |
| Tumor location | 0.5052 | ||
| Upper inner | 64 (14.5) | 48 (10.9) | |
| Low inner | 32 (7.3) | 27 (6.1) | |
| Upper lateral | 151 (34.3) | 170 (38.6) | |
| Low lateral | 37 (8.4) | 33 (7.5) | |
| Nipple deep | 32 (7.3) | 36 (8.2) | |
| NA | 124 (28.2) | 126 (28.6) | |
| TNM stage | 0.1417 | ||
| 0 | 47 (10.7) | 63 (14.3) | |
| I | 126 (28.6) | 139 (31.6) | |
| II | 136 (30.9) | 119 (27.0) | |
| III | 35 (8.0) | 39 (8.9) | |
| IV | 13 (3.0) | 5 (1.1) | |
| NA | 83 (18.9) | 75 (17.0) | |
| Molecular subtype | 0.2568 | ||
| HR+ | 249 (56.6) | 253 (57.5) | |
| HR+/HER2+ | 57 (13.0) | 67 (15.2) | |
| HER2+ | 23 (5.2) | 22 (5.0) | |
| TNBC | 47 (10.7) | 29 (6.6) | |
| NA | 64 (14.5) | 69 (15.7) | |
| Tumor site | 0.6980 | ||
| Single | 291 (66.1) | 307 (69.8) | |
| Multiple | 35 (8.0) | 31 (7.0) | |
| Multicenter | 15 (3.4) | 12 (2.7) | |
| NA | 99 (22.5) | 90 (20.5) | |